RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence
Salt Lake City, UT -- (SBWIRE) -- 12/21/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide chronic disease registry for at-risk populations (such as urban poor and American Indians) to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.
Details about the registry: http://www.remedymd.com/cer100/chronic_disease.html
Aligned with the Institute of Medicine’s Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD’s chronic disease registry for at-risk populations compares the effectiveness of various strategies (e.g., clinical interventions, selected social interventions [such as improving the built environment in communities and making healthy foods more available], combined clinical and social interventions) to prevent:
* Obesity
* Hypertension
* Diabetes
and heart disease in at-risk populations such as the urban poor and American Indians. The new registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.
“Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies” said Gary D. Kennedy, Founder and CEO of RemedyMD.
RemedyMD’s chronic disease registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to chronic disease research for at-risk populations, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.
In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of chronic disease researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/chronic_disease.html
RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to Leverage Chronic Disease Registry: http://www.remedymd.com/CER100/chronic_disease.html
Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html
Disease Registry Software:
http://www.remedymd.com/registries_home.html
Institute of Medicine’s Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html
About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider’s preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.
Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com